Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05850013
Other study ID # IRAS Reference: 321956
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 1, 2023
Est. completion date March 1, 2024

Study information

Verified date April 2023
Source Xim Limited
Contact Niall Mullen, MB BCh MRCPCH
Phone (0191) 5656256
Email niall.mullen@nhs.net
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A prospective basic science study for collection of training and testing data for development of Lifelight® Junior


Description:

This study will be hospital-based, including paediatric emergency department (PED), inpatient wards and outpatient departments). The participants will have their vital signs (such as heart rate, respiratory rate, oxygen saturation, blood pressure and temperature) measured using standard-of-care methods. Concurrent with this, videos of the participants' face/torso, and audio of the sounds made by the participants (cry, wheeze, cough) will be recorded. These data will later be used to train the Lifelight® Junior algorithms so that the technology can help in detection of illness and deterioration in children. Primary Objective Collect the data needed to develop Lifelight® Junior so that it can measure the heart rate, respiratory rate and oxygen saturation of children. Secondary Objective 1. Assess the feasibility of developing other (direct or indirect) measurement functions in Lifelight® Junior, including temperature, blood pressure, heart rate variability and audio analysis (cry, wheeze, cough). 2. Evaluate the impact of subject-specific variables on the vital sign measurements e.g., medication, cosmetics, facial/body hair and skin tone. 3. Obtain data to understand patient and parent/guardian/carer vital sign measurement habits and preferences 4. Assess the usability of Lifelight® Junior for measuring vital signs in children To ensure the study collects data that can train Lifelight® Junior in an efficient way, the recruitment should be divided as follows: - At least 12% of study participants should fall into each of the following age bands: - Age 0-1 - Age 1-2 - Age 2-5 - Age 5-11 - Age 11-14 - Age 14-18 - At least 40% of the study participants shall be male and at least 40% shall be female. - At least 40% of the study participants shall be each of the following: - Febrile (≥ 38°C) measured how? - Afebrile - Ill (as judged by the clinical staff), of whom at most 50% shall have an acute respiratory illness e.g., bronchiolitis, asthma, viral induced wheeze, pneumonia, croup, etc. - Well, including children with a minor injury Ideally, 15% of participants should have a Fitzpatrick skin tone of 4, 5 or 6 First reference to this - need to bring it in earlier and to reference it. However, this is not a hard target as achieving this figure is dependent on the demographic diversity of the study region.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date March 1, 2024
Est. primary completion date August 31, 2023
Accepts healthy volunteers No
Gender All
Age group N/A to 18 Years
Eligibility Inclusion Criteria: - Children (0-18 years old) attending the paediatric ED or who are inpatients on the paediatric wards at STSFT Exclusion Criteria: - Critically ill children (judged so by treating physicians), including unconscious children - Children who are non-compliant in terms of excessive movement during the measurement - Children of parents/guardians/carers who are non-English speakers

Study Design


Intervention

Device:
Lifelight Junior
Lifelight® is an app developed by xim that measures VS including heart rate, respiratory rate and blood pressure. All you need to do to have these vital signs measured is look at your smartphone or tablet camera for 20-40 seconds. The app has used data from over 1 million heartbeats to learn how to measure these vital signs in adults. The technology is already available for doctors and nurses to use with adult patients in some specific scenarios

Locations

Country Name City State
United Kingdom South Tyneside and Sunderland NHS Foundation Trust Sunderland

Sponsors (3)

Lead Sponsor Collaborator
Xim Limited Mind Over Matter Medtech Ltd, South Tyneside and Sunderland NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall outcome measure Train Lifelight algorithms across more extensive paediatric clinical ranges in 500 subjects 6 months
Primary Heart rate The following accuracy metrics are indicative minimum performance requirements for Lifelight® Junior. VISION-Junior should progress the technology towards these performance targets:
• Heart rate
o Root mean square error of 5 bpm or lower
6 months
Primary Respiratory rate The following accuracy metrics are indicative minimum performance requirements for Lifelight® Junior. VISION-Junior should progress the technology towards these performance targets:
• Respiratory rate
o Maximum error of 5 breaths per minute for 100% of the measurements
6 months
Primary Oxygen saturation level (percentage) The following accuracy metrics are indicative minimum performance requirements for Lifelight® Junior. VISION-Junior should progress the technology towards these performance targets:
• Oxygen saturation
o Maximum error tolerance of 4%.
6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)